Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.
Upamostat (WX-671, umorestat) is a Urokinase-type Plasminogen Activator (uPA) inhibitor.
Upamostat (WX-671, umorestat) is a Urokinase-type Plasminogen Activator (uPA) inhibitor.
Upamostat (WX-671, umorestat) is a Urokinase-type Plasminogen Activator (uPA) inhibitor.
UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM which is ~27-fold selective against PARP1.
UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM which is ~27-fold selective against PARP1.
UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM which is ~27-fold selective against PARP1.
UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.
UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.
UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.
UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.
Uprosertib (GSK2141795) is a potent and selective pan-Akt inhibitor with IC50 values of 180 nM for Akt1, 328 nM for Akt2, and 38 nM for Akt3 respectively (Clinical phase 1).